Metsera, A Wholly Owned Subsidiary Of Pfizer
Clinical trials sponsored by Metsera, A Wholly Owned Subsidiary Of Pfizer, explained in plain language.
-
New obesity drug duo enters human testing
Disease control Recruiting nowThis study tests whether combining two experimental drugs (MET233 and MET097) can safely help people with obesity or overweight lose weight. About 132 adults with a BMI of 27 or higher, some with type 2 diabetes, will receive either the drug combination or a placebo. The main goa…
Phase: PHASE1, PHASE2 • Sponsor: Metsera, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New weekly shot could help shed pounds in major obesity trial
Disease control Recruiting nowThis study tests a new once-weekly injection called MET097 in 3500 adults with obesity or overweight who also have weight-related health issues like high blood pressure or sleep apnea. The goal is to see how much weight participants lose over 64 weeks and whether the treatment is…
Phase: PHASE3 • Sponsor: Metsera, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 06, 2026 16:15 UTC